NEVIRAPINE

Main information

  • Trade name:
  • NEVIRAPINE APOTEX nevirapine 200 mg tablet blister pack
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • NEVIRAPINE APOTEX nevirapine 200 mg tablet blister pack
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 220945
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

220945

NEVIRAPINE APOTEX nevirapine 200 mg tablet blister pack

ARTG entry for

Medicine Registered

Sponsor

Apotex Pty Ltd

Postal Address

PO Box 280,NORTH RYDE BC, NSW, 1670

Australia

ARTG Start Date

17/03/2016

Product category

Medicine

Status

Active

Approval area

Drug Safety Evaluation Branch

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. NEVIRAPINE APOTEX nevirapine 200 mg tablet blister pack

Product Type

Single Medicine Product

Effective date

17/03/2016

Warnings

See Product Information and Consumer Medicine Information for this product

Standard Indications

Specific Indications

Nevirapine immediate-release tablets in combination with antiretroviral agents are indicated for the treatment of HIV-1 infection in adults and adolescents

over the age of 16 years.,Resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an

antiretroviral agent. Therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Blister Pack

PVC/Al

24 Months

Store below 30

degrees Celsius

Neither child resistant

closure nor restricted

flow insert

Store in Original

Container

Pack Size/Poison information

Pack Size

Poison Schedule

(S4) Prescription Only Medicine

Components

1. NEVIRAPINE APOTEX nevirapine 200 mg tablet blister pack

Dosage Form

Tablet

Route of Administration

Oral

Visual Identification

white, oval shaped scored biconvex tablets with engraved "APO" and bisect

on one side and "NAV" bisect "200" on the other side

Active Ingredients

Nevirapine

200 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 26.11.2017 at 01:51:37 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

31-10-2018

Viramune (Boehringer Ingelheim International GmbH)

Viramune (Boehringer Ingelheim International GmbH)

Viramune (Active substance: nevirapine) - Centralised - Yearly update - Commission Decision (2018)7337 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety